223 related articles for article (PubMed ID: 31669399)
1. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.
DeFilipp Z; Ancheta R; Liu Y; Hu ZH; Gale RP; Snyder D; Schouten HC; Kalaycio M; Hildebrandt GC; Ustun C; Daly A; Ganguly S; Inamoto Y; Litzow M; Szer J; Savoie ML; Hossain N; Kharfan-Dabaja MA; Hamadani M; Reshef R; Bajel A; Schultz KR; Gadalla S; Gerds A; Liesveld J; Juckett MB; Kamble R; Hashmi S; Abdel-Azim H; Solh M; Bacher U; Lazarus H; Olsson R; Cahn JY; Grunwald MR; Savani BN; Yared J; Rowe JM; Cerny J; Chaudhri NA; Aljurf M; Beitinjaneh A; Seo S; Nishihori T; Hsu JW; Ramanathan M; Alyea E; Popat U; Sobecks R; Saber W
Biol Blood Marrow Transplant; 2020 Mar; 26(3):472-479. PubMed ID: 31669399
[TBL] [Abstract][Full Text] [Related]
2. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
3. The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era.
Schmidt S; Liu Y; Hu ZH; Williams KM; Lazarus HM; Vij R; Kharfan-Dabaja MA; Ortí G; Wiernik PH; Weisdorf D; Kamble RT; Herzig R; Wirk B; Cerny J; Bacher U; Chaudhri NA; Nathan S; Farhadfar N; Aljurf M; Gergis U; Szer J; Seo S; Hsu JW; Olsson RF; Maharaj D; George B; Hildebrandt GC; Agrawal V; Nishihori T; Abdel-Azim H; Alyea E; Popat U; Sobecks R; Scott BL; Holter Chakrabarty J; Saber W
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1137-1143. PubMed ID: 32062061
[TBL] [Abstract][Full Text] [Related]
4. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.
Warlick E; Ahn KW; Pedersen TL; Artz A; de Lima M; Pulsipher M; Akpek G; Aljurf M; Cahn JY; Cairo M; Chen YB; Cooper B; Deol A; Giralt S; Gupta V; Khoury HJ; Kohrt H; Lazarus HM; Lewis I; Olsson R; Pidala J; Savani BN; Seftel M; Socié G; Tallman M; Ustun C; Vij R; Vindeløv L; Weisdorf D
Blood; 2012 Apr; 119(17):4083-90. PubMed ID: 22408257
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.
Chalandon Y; Sbianchi G; Gras L; Koster L; Apperley J; Byrne J; Salmenniemi U; Sengeloev H; Aljurf M; Helbig G; Kinsella F; Choi G; Reményi P; Snowden JA; Robin M; Lenhoff S; Mielke S; Passweg J; Broers AEC; Kröger N; Yegin ZA; Tan SM; Hayden PJ; McLornan DP; Yakoub-Agha I;
Am J Hematol; 2023 Jan; 98(1):112-121. PubMed ID: 36266607
[TBL] [Abstract][Full Text] [Related]
6. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia - A Single-institution Retrospective Study.
Fujita S; Kasahara H; Kato J; Koda Y; Shiroshita K; Yamaguchi K; Okayama M; Abe R; Kikuchi T; Shimizu T; Mori T; Kataoka K; Okamoto S
Intern Med; 2024 Jun; 63(11):1549-1562. PubMed ID: 37899244
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT.
Masouridi-Levrat S; Olavarria E; Iacobelli S; Aljurf M; Morozova E; Niittyvuopio R; Sengeloev H; Reményi P; Helbig G; Browne P; Ganser A; Nagler A; Snowden JA; Robin M; Passweg J; Van Gorkom G; Wallet HL; Hoek J; Blok HJ; De Witte T; Kroeger N; Hayden P; Chalandon Y; Agha IY
Bone Marrow Transplant; 2022 Jan; 57(1):23-30. PubMed ID: 34599284
[TBL] [Abstract][Full Text] [Related]
9. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
[TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia.
Bar M; Radich J
J Natl Compr Canc Netw; 2013 Mar; 11(3):308-15. PubMed ID: 23486457
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation.
Tachibana T; Kondo T; Uchida N; Doki N; Takada S; Takahashi S; Yano S; Mori T; Kohno A; Kimura T; Fukuda T; Atsuta Y; Nagamura-Inoue T;
Transplant Cell Ther; 2022 Jun; 28(6):321.e1-321.e8. PubMed ID: 35296447
[TBL] [Abstract][Full Text] [Related]
12. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.
Shanavas M; Messner HA; Kamel-Reid S; Atenafu EG; Gupta V; Kuruvilla J; Kim DD; Uhm J; Lambie A; Ellis L; Lipton JH
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):87-92. PubMed ID: 24252361
[TBL] [Abstract][Full Text] [Related]
13. Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.
Wu J; Chen Y; Hageman L; Francisco L; Ness EC; Parman M; Kung M; Watson JA; Weisdorf DJ; Snyder DS; McGlave PB; Forman SJ; Arora M; Armenian SH; Bhatia R; Bhatia S
Cancer; 2019 Nov; 125(22):4033-4042. PubMed ID: 31412155
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis.
Chaudhury S; Sparapani R; Hu ZH; Nishihori T; Abdel-Azim H; Malone A; Olsson R; Hamadani M; Daly A; Bacher U; Wirk BM; Kamble RT; Gale RP; Wood WA; Hale G; Wiernik PH; Hashmi SK; Marks D; Ustun C; Munker R; Savani BN; Alyea E; Popat U; Sobecks R; Kalaycio M; Maziarz R; Hijiya N; Saber W
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1056-1064. PubMed ID: 26964698
[TBL] [Abstract][Full Text] [Related]
16. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
Shimazu Y; Murata M; Kondo T; Minami Y; Tachibana T; Doki N; Uchida N; Ozawa Y; Yano S; Fukuda T; Kato J; Ara T; Eto T; Ishikawa J; Nakamae H; Tanaka J; Ichinohe T; Atsuta Y; Nagamura-Inoue T;
Hematol Oncol; 2022 Aug; 40(3):442-456. PubMed ID: 35394658
[TBL] [Abstract][Full Text] [Related]
17. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?
Suttorp M; Yaniv I; Schultz KR
Biol Blood Marrow Transplant; 2011 Jan; 17(1 Suppl):S115-22. PubMed ID: 21195300
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era.
Pasquini MC
Hematology; 2012 Apr; 17 Suppl 1():S79-82. PubMed ID: 22507787
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.
Kondo T; Nagamura-Inoue T; Tojo A; Nagamura F; Uchida N; Nakamae H; Fukuda T; Mori T; Yano S; Kurokawa M; Ueno H; Kanamori H; Hashimoto H; Onizuka M; Takanashi M; Ichinohe T; Atsuta Y; Ohashi K
Am J Hematol; 2017 Sep; 92(9):902-908. PubMed ID: 28543934
[TBL] [Abstract][Full Text] [Related]
20. Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era.
Savoie ML; Bence-Bruckler I; Huebsch LB; Lalancette M; Hillis C; Walker I; Lipton JH; Forrest DL; Kim DDH
Leuk Res; 2018 Oct; 73():67-75. PubMed ID: 30227318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]